Anixa Biosciences announced that the Mexican Institute of Industrial Property (IMPI) has granted a Notice of Allowance for a patent covering its breast‑cancer vaccine technology, extending the company’s intellectual‑property protection into Mexico as of January 27 2026.
Mexico has a higher incidence of triple‑negative breast cancer (23.1 %) and a greater proportion of later‑stage diagnoses compared with the United States, creating a significant unmet medical need that Anixa’s vaccine could address.
The vaccine, which targets human α‑lactalbumin expressed in certain breast cancers, achieved a 74 % immune‑response rate in a recently completed Phase 1 trial and met all primary endpoints. The patent is licensed exclusively from the Cleveland Clinic, underscoring the collaborative development model that has driven the program’s progress.
Dr. Amit Kumar, Chairman and CEO, said the allowance “continues the broad international recognition of the novelty and potential of our breast‑cancer vaccine” and highlighted the company’s intent to pursue regulatory submissions and commercial activities in Mexico once the vaccine’s safety and efficacy profile is fully established.
The patent allowance strengthens Anixa’s global portfolio, positions the company to capitalize on a high‑need market, and may open the door to strategic partnerships or licensing opportunities that could accelerate the vaccine’s worldwide commercialization.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.